Nautilus Biotechnology, Inc. — Form 8-K
Filed September 11, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Nautilus Biotechnology entered into an at-the-market (ATM) sales agreement with TD Securities (USA) LLC on September 11, 2026, permitting the company to sell up to $125,000,000 of common stock at market prices over time. TD Securities will act as agent/principal and receive compensation up to 3.0% of gross proceeds. This replaces an earlier ATM agreement dated February 24, 2024.
Why this rating
ATM of $125M (3.5× company market cap) is material for capital access, but actual proceeds depend on execution and stock price. Positive signal of investor confidence; neutral risk if not overused.
Extracted items
Price action (we called it positive)
before filing · preread $1.01 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.